Last reviewed · How we verify

Befizal — Competitive Intelligence Brief

Befizal (BEZAFIBRATE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bezafibrate. Area: Metabolic.

marketed bezafibrate Fatty acid-binding protein, intestinal Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Befizal (BEZAFIBRATE).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Befizal TARGET BEZAFIBRATE marketed bezafibrate Fatty acid-binding protein, intestinal
Trilipix CHOLINE FENOFIBRATE AbbVie marketed Peroxisome Proliferator Receptor alpha Agonist Fatty acid-binding protein, intestinal 2008-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bezafibrate class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Befizal — Competitive Intelligence Brief. https://druglandscape.com/ci/bezafibrate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: